Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin

Lookup NU author(s): Dr David Sheridan, Dr David Price, Dr Matthias Schmid, Emeritus Professor Geoffrey Toms, Dr Peter Donaldson, Dr R Neely, Professor Margaret Bassendine

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Hepatitis C virus (HCV) co-opts very-low-density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB-100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides. To determine whether baseline lipid levels predicted treatment outcome. Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti-viral agents interferon-alpha and ribavirin; 165 had a sustained virological response (SVR). Pre- and post-treatment nonfasting lipid profiles were measured and non-high-density lipoprotein (non-HDL) cholesterol (i.e. apoB-associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome. There was an independent association between higher apoB-associated cholesterol (non-HDL-C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non-HDL-C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre-treatment non-HDL-C = 2.8 mmol/L, SVR = 3.6 mmol/L, P


Publication metadata

Author(s): Sheridan DA, Price DA, Schmid ML, Toms GL, Donaldson P, Neely D, Bassendine MF

Publication type: Article

Publication status: Published

Journal: Alimentary Pharmacology & Therapeutics

Year: 2009

Volume: 29

Issue: 12

Pages: 1282-1290

Date deposited: 18/05/2010

ISSN (print): 0269-2813

ISSN (electronic): 1365-2036

Publisher: Wiley-Blackwell Publishing Ltd.

URL: http://dx.doi.org/10.1111/j.1365-2036.2009.04012.x

DOI: 10.1111/j.1365-2036.2009.04012.x


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Newcastle Healthcare Charity
Schering Plough Limited (UK)
Wellcome Trust
G0502028Medical Research Council

Share